Theralase Quarterly Newsletter - December 2011

An update for clients, investors and employees

Theralase’s Patented Photo Dynamic Compound (PDC) Effective in Destruction of Cancerous Tumours in Live Animals

Theralase announced on December 1^st that its patented light activated PDC technology was successful in destroying cancerous tumours located under the skin of a live animal. We are excited that our PDC technology has achieved this critical milestone because we have now validated our technology in the destruction of cancerous tumours in live animals. The Theralase PDC treatment was successful and well tolerated by the animals and as a result, this preclinical success will help the Company to identify the leading PDC to take forward for additional animal and human cancer destruction applications. Now that our PDC technology has been proven successful in the destruction of cancerous tumours in animals, this may lead to a new significant revenue stream for the Company in the destruction of cancerous tumours in companion animals and humans in the not too distant future.

Theralase Light Activated Photo Dynamic Compounds Successfully Destroy E. coli Bacteria

Theralase has developed a new application for its patented Photo Dynamic Compounds (PDCs); specifically, the destruction of Escherichia coli, commonly known as E. coli, a widely prevalent disease causing bacteria. Theralase announced on September 14^th, that our research demonstrated that our Photo Dynamic Therapy (PDT) destruction of E. coli bacteria is effective and represents a significant opportunity in the area of disinfection and sterilization of bacterial pathogens that may cause serious and potentially life-threatening illness. Commercialization of these technologies becomes more and more apparent, as our research and development progresses, allowing us the opportunity to introduce these technologies to the world in a variety of diverse applications. The next steps for Theralase will be to prove out the technology further in a lab setting and then develop a pilot project with a major food manufacturer.

Theralase and George Brown College Join in Government-Funded Research to Combat Food Contamination

In the wake of many outbreaks of consumer food contaminations associated with microbial pathogens such as Listeria monocytogenes (Listeria) and Escherichia coli (E. coli) and their various strains, Theralase completed a the study with George Brown College to determine the feasibility of using our patented PDCs for sanitation in the food service, food manufacturing and medical industries. Given their history and pedigree in culinary arts and additional focus on food applied research, the George Brown College Centre for Hospitality and Culinary Arts was a perfect partner for applied research in new and innovative sanitation protocols and techniques using the company’s patented lasers and photo dynamic compounds. The results proved that the Theralase PDC technology is highly effective in the destruction of food related pathogens.

Theralase Introduces Low Priced Laser Series - New TLC-900 Laser Series Offers Theralase’s Renowned Clinical Performance at Lower Prices

On November 17^th Theralase launched a new version of the high performance Theralase TLC-1000 therapeutic medical laser series, known as the Theralase TLC-900 series, which effectively eliminates the controller and allows the practitioner to operate the laser probes independently. This TLC-900 system allows the practitioner the ability to benefit from the high performance Theralase laser system technology, albeit with less features and versatility than the TLC-1000 series, but at an overall cost savings. We believe that this will open up the therapeutic laser market and give practitioners the ability to choose a high performing product, such as the Theralase, at the same price points as lower end, non-effective, competitive technology.

Theralase Closes Equity Financing

On October 25^th Theralase Technologies Inc. announced that it closed a non-brokered private placement of 1,050,000 units at a price of Cdn $0.40 per Unit for gross proceeds of Cdn $420,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant. Each whole Warrant entitles the purchaser to purchase one additional common share in the capital of the Company until October 25, 2013 at a price of Cdn $0.60 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring February 25, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network.

• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria in the area of food safety.

• TLC-1000 and TLC-900 series therapeutic medical laser marketing and sales expansion into the US.

• TLC-2000 therapeutic medical biofeedback laser commercialization.

Theralase Publishes White Paper

On October 27^th Theralase released a pivotal White Paper written by Chief Scientific Officer,  

Arkady Mandel, MD, Ph.D., D.Sc. entitled

 “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)”

Low Level Laser Therapy (LLLT) is a rapidly growing modality used in the rehabilitation and physical therapy markets. A number of safe and beneficial therapeutic effects of LLLT have been reported in numerous clinical conditions; however, despite many reports of positive findings from experiments conducted in-vitro, in-vivo animal models and in randomized controlled clinical trials worldwide, the use of this scientifically proven, clinically effective, non-invasive and anti-inflammatory human modality has yet to find mainstream adoption by medical doctors.

The aim of the White Paper is to:

1) introduce the unfamiliar reader, with some medical background, to the contemporary concept of LLLT and its pathophysiological significance,

2) review the role of the mitochondrial pathway in the mechanisms of LLLT,

3) provide necessary practical guidance based on scientific and clinical experience,

4) assist manufacturers in their research and development,

5) help health care practitioners choose and use an adequate light therapy device,

6) outline the prospects of LLLT as an avenue to treat chronic inflammation and pain and to aid in an effective clinical practice.

The White Paper may be accessed from www.theralase.com.

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the newly released TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the third quarter of 2012, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase a significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 Therapeutic Medical Laser platform to pay for its future growth in the form of the launch of the TLC-900 series, the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

For more information please contact:

Roger Dumoulin-White                                                                                

President & CEO,                            

416-447-8455 ext. 225                                   

rwhite@theralase.com                

Greg Bewsh

Director of Investor Relations,

416-447-8455 ext. 262

gbewsh@theralase.com      

Survey of Chiropractic Profession Finds That Laser Care Increases Revenues and Patients Heal Faster

By Donald M. Petersen Jr., BS, HCD(hc), FICC(h)

An impressive 92% of DCs who use laser care would recommend other DCs add therapeutic lasers to their practice, a Dynamic Chiropractic email survey has found. Not surprisingly perhaps, 75% of those who would recommend it to peers said it is because these devices have proven to be a very effective part of their treatment strategy, while 45% said their patients enjoy laser care and have referred others as a result of the laser care.

As Dr. Todd Austin of Illinois remarked: "Our clinic's low level lasers improve ROM, decrease inflammation and edema, help to increase oxygenation of the damages target issues, speed up the healing process and (even more importantly in my opinion) increase the damaged tissue's ability to handle additional stress. The bottom line is: if there are damaged cells or tissues present, LLLT (low-level laser therapy) will usually be of benefit."

 Equally impressive are the business results our respondents reported: Forty percent said they have seen an increase in practice income as a result of incorporating laser therapy into their treatments. Another 26% reported that the reputation of their practice has improved.

Who Uses Lasers and How

 Approximately a third of DCs utilize laser care on half or more of their patients. When asked about the patient complaints they had the most success addressing with laser care treatment, they responded:

 ■Extremity Pain - 77%

■Neck & Shoulder Pain - 72%

■Back Pain - 60%

■TMJ Disorders - 41%

■Disc Herniation - 29%

■Disc Herniation with Radiculopathy - 27%

 Laser care fits well into the chiropractic philosophy with 94% of DC users totally or somewhat agreeing that they "believe in the philosophy of laser care."

One doctor who took the survey noted: "Overall, I find it a very effective therapy when used alone and works excellently with Chiropractic adjustments." Stephen Fedele, Jr., DC, of California agrees: "It speeds recovery and shows that they can recover without drugs and surgery."

Quality is not an issue as 90% totally or somewhat agreed that they are "confident in the quality of my laser." And while price can always be a challenge, just under 60% agreed (totally or somewhat) that their laser was "very affordable." Dr. Stephen M. Savoie of Florida said laser therapy "is an extremely effective modality that provides pain relief and recovery with less effort on the doctor's part at an affordable price."

 Why Not Use Lasers?

 So why don't more doctors of chiropractic use lasers in their practice? The answer appears may be a lack of information.

Only 45% of DC users totally agreed that they were ready to use their laser based upon the "information provided with my laser." Many DCs gained additional information before and after they made their purchase from a number of sources.

 This same theme is echoed by doctors who don't current own lasers, but are considering making a purchase. Less than half are "very" or "somewhat" confident in their "understanding of lasers and their application in your practice."

 When asked what additional information would assist them in making their decision, doctors who considering purchasing a laser device for their practice stated overwhelmingly preferred they wanted in writing or from attending seminars and webinars.

 Laser Preferences

 One of the more interesting data points to emerge from this survey was the apparent lack of differentiation between "high level" lasers (Class IV/above 500 milliwatts) and "low level" lasers (Class III/below 500 milliwatts). When asked which type of laser these doctors are considering to purchase, 54% stated "either." This may also suggest that doctors believe that both are equally effective.

 Lasers are clearly seen as a valuable clinical tool by those DCs who are currently using them in their practice. They are seen as an effective adjunct to the adjustment, fitting both philosophically and financially. In addition they increase both income and referrals for almost half of the DCs who use them. According to William J. Kneebone, DC, of California "Therapeutic laser provides the most rapid and predictable relief of any modality that I've used in my 32 years of practice.

Those doctors thinking about adding lasers to their care should spend a good amount of time learning about how lasers work and what specific products are available. DCs will want to be confident that they are purchasing the right therapeutic laser for their practice.

For more information, please call 1-866-843-5273 or visit www.theralase.com

End of Year Demo Sale on the #1 Rated Therapeutic Laser in the World

	Please call 1.866.843.5273 or email sales@theralase.com  to find theTheralase that's right for you, at a price that can't be beat.  *Sales order must be signed and product delivered prior to December 31, 2011 toqualify for this promotion.

Theralase’s Patented Photo Dynamic Compound (PDC) Effective in Destruction of Cancerous Tumours in Live Animals

Theralase’s Patented Photo Dynamic Compound (PDC) Effective in Destruction of Cancerous Tumours in Live Animals FOR IMMEDIATE RELEASETORONTO ONTARIO - December 1st, 2011Previously released November 29, 2011 Theralase Technologies Inc. (TSXV: TLT) announced previously that its patented light activated PDC technology was successful in destroying cancerous tumours located under the skin of a live animal. Due to overwhelming investor interest in the November 29, 2011 press release, the Company has provided this press release for further clarity on this important milestone in the history of the Company. Roger Dumoulin-White, who is the President and CEO of Theralase Inc. stated, "Theralase is excited that our PDC technology has achieved this critical milestone because we have now validated our technology in the destruction of cancerous tumours in live animals. The Theralase PDC treatment was successful and well tolerated by the animals and as a result, this preclinical success will help the Company to identify the leading PDC to take forward for additional animal and human cancer destruction applications. Now that our PDC technology has been proven successful in the destruction of cancerous tumours in animals, this may lead to a new significant revenue stream for the Company in the destruction of cancerous tumours in companion animals and humans in the not too distant future." About Theralase Technologies Inc. Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com. regulatory filings may be viewed by visiting www.sedar.com This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. Downloads: Download the Press Release For more information contact: Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. 416-447-8455 ext. 225 rwhite@theralase.com Greg Bewsh Director of Investor Relations 416-447-8455 ext. 262 gbewsh@theralase.com Regards, The Theralase Team Web Sites: www.theralase.com Theralase Laser Clinic Clinic Locator

Theralase’s Patented Photo Dynamic Compounds (PDCs) Effective in Destruction of Cancerous Tumours in a Live Animal Model

Theralase’s Photo Dynamic Compounds (PDCs) Effective in Destruction of Cancerous Tumours in an In-vivo Model Theralase’s Patented PDCs Have Successfully Achieved Efficacy In-vivo FOR IMMEDIATE RELEASE TORONTO ONTARIO - November 29th, 2011 Theralase Technologies Inc. (TSXV: TLT) announced today that it has successfully destroyed cancer cells in an in-vivo subcutaneous malignant tumour model. These results now confirm in a well established in-vivo model what has been demonstrated previously in in-vitro cancer cell lines model, which is a high kill rate of cancer cells when exposed to Theralase’s patented light activated PDCs. Dr. Lothar Lilge, PhD, Senior Scientist at the Ontario Cancer Institute, Princess Margaret Hospital stated, "It was critical to establish the relevance of prior successful in-vitro destruction for three cancer cell lines at greater than 99% efficacy to a subcutaneous in-vivo tumour model to see if similar results could be achieved The results in this model of the first Photo Dynamic Compound (PDCs) tested demonstrates significant destruction of tumours in this model, exemplified by histology showing tumour necrosis and wide spread eradication of the cancer cells. These results support the high therapeutic potential of Theralase’s patented Type 1 PDCs towards cancer destruction in-vivo. We continue to work towards increasing the efficacy by optimizing the laser source emission utilized in the activation of the PDCs." Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer at Theralase Inc., said, "We have made a large advancement towards the understanding of the mechanism by which our patented PDCs can be utilized to effectively destroy cancerous tumours in an established in-vivo subcutaneous cancer model. This is a very significant milestone in our Research and Development path, proving that Theralase’s Photo Dynamic Compounds (PDCs), which use a virtually non-toxic photosensitizer activated by visible light can achieve local destruction of malignant tumour in-vivo. We are planning to present these exciting results at the annual SPIE International Society for Optics and Photonics conference in 2012." Roger Dumoulin-White, President and CEO of Theralase Inc. expressed, "Theralase is excited that our patented PDCs have successfully achieved efficacy in an in-vivo subcutaneous model. This is an important milestone for the Company because we have now demonstrated the ability of the patented PDCs to destroy cancer cells in both an in-vitro and in an in-vivo cancer model, when light activated. The therapy with the Theralase PDC compound was well tolerated by the host. Theralase is well on its way to prove the viability of its technology to increase the oncologist’s options for a successful treatment of cancer. What our skilled scientific and preclinical researchers have unveiled today is nothing short of the fact that the first Theralase PDC tested in-vivo from our library of compounds is effective both in-vitro and in-vivo." There is an earnings conference call and corporate update scheduled for November 30th, 2011 at 9:00am ET. The call in number is 1-866-440-8936, the conference ID is 8791351#. The call will be hosted by Roger Dumoulin-White, President & CEO of Theralase Technologies Inc. About Theralase Technologies Inc. Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com. regulatory filings may be viewed by visiting www.sedar.com This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. Downloads: Download the Press Release  For more information contact: Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. 416-447-8455 ext. 225 rwhite@theralase.com  Greg Bewsh  Director of Investor Relations 416-447-8455 ext. 262 gbewsh@theralase.com Regards, The Theralase Team Web Sites: www.theralase.com Theralase Laser Clinic Clinic Locator  Follow Us: Facebook Twitter Blogger

Theralase Announces Q3 2011 Financials

Toronto, Ontario – November 28, 2011 Theralase Technologies Inc. (TSX-V: TLT) announced its third quarter 2011 financials today.

Revenue remained relatively constant year over year with total revenue for the three month period ending September 30, 2011 at $453,212, compared to $424,879 for the same period in 2010, an increase of 6.7%.

Selling expenses increased for the three month period ending September 30, 2011 to $237,409 compared to $177,944 for the same period the previous year, an increase of 33.4%. The increase is primarily due to increases in the sales and marketing costs associated with the new Territory Sales Managers (TSMs) hired for the United States sales and market expansion.

Administrative expenses remained constant at $280,587 for the three month period ending September 30, 2011 compared to $283,908 for the same period the previous year, with the minor reduction primarily due to decreased expenditures on administrative staff.

Research and development costs remained relatively constant at $225,439 for the three month period ending September 30, 2011 compared to $228,720 for the same period in 2010. The expenditures are primarily due to the development costs associated with the patented TLC-2000 biofeedback therapeutic laser system, scheduled to be commercially launched in 2012 and costs associated with the research and development of Theralase’s patented Photo Dynamic Compounds (PDCs) being developed for cancer, virus and bacteria destruction.  

Roger Dumoulin‐White, President and CEO of Theralase Technologies Inc. stated, “The net loss for the three month period ended September 30, 2011 was $423,929 which included $16,122 of non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements). The company expenses the future product development costs of the patented TLC‐2000 biofeedback therapeutic laser system and TLC‐3000 Photo Dynamic Compound (PDC) technology from existing TLC‐1000 therapeutic laser product sales, resulting in the overall net loss. This investment in our future will secure our position as an international leader in medical laser technology both in the therapeutic tissue healing space as well as the tissue destruction space for decades to come.”

During the quarter, Theralase announced that its patented PDCs have shown an ability to destroy listeria monocytogenes bacteria in-vitro when light activated, in new research performed at the Princess Margaret Hospital, University Health Network. Future applications of the PDC technology in bacteria destruction may involve: food safety through food processing equipment sterilization, hospital treatment room sterilization, medical equipment sterilization, bacterial load elimination in wounds and other bacteria destruction applications. Theralase in developing and commercializing this new application of our PDC technology plans to work with a variety of organizations, including: food processing organizations, academic institutions, hospitals, practitioners and medical equipment manufacturers interested in bacterial destruction applications.

As well, during the quarter, Theralase announced it has successfully expanded its cancer destruction applications. This new research expands the application of Theralase’s patented PDC technology in the cancer field and introduces the potential for a successful impact on two devastating forms of cancer; specifically, brain and colon cancer. Theralase’s research has demonstrated a significant kill rate of greater than 99% in specific human brain and colon cancer cells lines. These results now lay the groundwork for further preclinical trials, which if proven successful may lead to human clinical trials. Theralase plans to aggressively pursue commercialization of its ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase also plans to continue its research and development to optimize its PDCs, from the same platform, to destroy a variety of life threatening cancers.

Theralase also recently announced the launch of a new version of the high performance Theralase TLC-1000 therapeutic medical laser series, known as the Theralase TLC-900 series, which effectively eliminates the controller and allows the practitioner to operate the laser probes independently. This TLC-900 system allows the practitioner the ability to benefit from the high performance Theralase laser system technology, albeit with less features and versatility than the TLC-1000 series, but at an overall cost savings.

Subsequent to the end of the quarter, Theralase completed a non‐brokered private placement which raised gross proceeds of $420,000 by issuing 1,050,000 Units to investors at a price of $0.40 per Unit. Each Unit consists of one common share in the capital of the Company and one‐half of one non‐transferable common share purchase warrant. Each whole Warrant entitles the purchaser to purchase one additional common share in the capital of the Company until October25, 2013 at a price of $0.60 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a mandatory four month hold period, imposed by the TSX Venture Exchange, expiring February 25, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company’s prospects in a number of areas; specifically:

·         Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network

·         Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria in the area of food safety

·         TLC‐1000 therapeutic medical laser USA sales and marketing expansion

·         TLC‐2000 therapeutic medical biofeedback laser commercialization

Theralase is preparing for significant growth in the 4^th quarter of 2011 and in 2012 as the Company expands its sales and marketing efforts in the US and internationally, launches its new controllerless laser series and prepares for the launch of its patented TLC‐2000 biofeedback therapeutic laser in 2012.

The complete consolidated financial statements and MD&A for the three and nine months ending September 30, 2011 can be found at www.theralase.com and www.sedar.com.

There is an earnings conference call and corporate update scheduled for November 30^th, 2011 at 9:00am ET. The call in number is 1-866-440-8936, the conference ID is 8791351#. The call will be hosted by Roger Dumoulin-White, President & CEO of Theralase Technologies Inc.

About Theralase Technologies Inc.

Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses, as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information

Roger Dumoulin-White                                                                                

President & CEO,                            

416-447-8455 ext. 225                                   

rwhite@theralase.com

Kristina Hachey

CFO

416-447-8455 x224

khachey@theralase.com

Greg Bewsh

Director of Investor Relations,

416-447-8455 ext. 262

gbewsh@theralase.com  

Theralase Introduces Low Priced Laser Series

Theralase Introduces Low Priced Laser Series New TLC-900 Laser Series Offers Theralase’s Renowned Clinical Performance at Lower Prices FOR IMMEDIATE RELEASE TORONTO ONTARIO - November 17th, 2011 Theralase Technologies Inc. (TSXV: TLT) announced today that it has launched a new version of the high performance Theralase TLC-1000 therapeutic medical laser series, known as the Theralase TLC-900 series, which effectively eliminates the controller and allows the practitioner to operate the laser probes independently. This TLC-900 system allows the practitioner the ability to benefit from the high performance Theralase laser system technology, albeit with less features and versatility than the TLC-1000 series, but at an overall cost savings. Roger Dumoulin-White, President and CEO of Theralase stated, "The Theralase TLC-900 series has been designed by our engineering team for practitioners, who have specific applications of our technology in mind. By selecting only one of our 3 styles of laser probes and not requiring the ability to switch back and forth between laser probes, the practitioner is able to eliminate the controller as well as the laser probes that are not required, thus lowering the overall purchase price of the product. Practitioners are still able to utilize the same superpulsed dual wavelength laser technology, with its high patient efficacy and low hands-on treatment time, but at a more economical price point. We introduced this new technology to open up our product line to allow practitioners the ability to integrate state-of-the-art Theralase therapeutic laser technology into their practice, but without all of the features or all of the laser probes of the TLC-1000 laser series. Now every medical practitioner can add a high performing Theralase therapeutic laser into their practice to treat chronic pain, inflammation, wound healing and neural muscular-skeletal conditions, at a more cost effective price. Theralase believes that this will open up the therapeutic laser market and give practitioners the ability to choose a high performing product, such as the Theralase, at the same price points as lower end, non- effective, competitive technology." Theralase has published a White Paper covering the science and cellular mechanisms of how Low Level Laser Therapy (LLLT) works. It may be easily accessed by going to www.theralase.com/www/whitepapers.php to download the free publication. About Theralase Technologies Inc. Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com. regulatory filings may be viewed by visiting www.sedar.com This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. Downloads: Download the Press Release  For more information contact: Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. 416-447-8455 ext. 225 rwhite@theralase.com  Greg Bewsh  Director of Investor Relations 416-447-8455 ext. 262 gbewsh@theralase.com Regards, The Theralase Team Web Sites: www.theralase.com Theralase Laser Clinic Clinic Locator  Follow Us: Facebook Twitter Blogger

YOU ARE INVITED TO AN INTRODUCTORY WORKSHOP ON COLD LASER THERAPY

YOU ARE INVITED TO AN INTRODUCTORY WORKSHOP ON COLD LASER THERAPY

This 2 hour session is for DCs, PTs, RMTs and MDs interested in introductory information on cold laser therapy for injury healing. The session includes presented material and an interactive workshop. Thinking of adding cold laser to your practice? Take advantage of this great opportunity. Workshop Objectives Understand the basic physics and theories of laser effects on tissue repair and pain reduction Learn the features and parameters of laser technology Review indications and contraindications for laser therapy Explore operation of a laser system and application to specific injuries through a hands-on workshop. When Tuesday December 6th, 2011 6:30-8:30 pm Where Theralase Laser and Rehabilitation Center 29 Gervais Drive Suite 102 (Don Mills/Eglinton) Fee $30 (Includes Dinner)  Agenda 6:30-7:30 Dinner and Presentation 7:30-8:30 Interactive Laser Workshop About the Speaker: Dr. Rhonda Mostyn is the Director of Clinical Services and Training at Theralase, a leader in cold laser technology. Dr. Mostyn has trained and educated hundreds of health practitioners and students through seminars and webinars on introductory and advanced topics in laser therapy. She has lectured for the continuing education departments at Logan College, National University of Health Sciences, Southern California University of Health Sciences and the Canadian Memorial Chiropractic College. Reserve your spot today. Limited to the first 25 registrants. Call: 1.866.843.5273 x 243 or rmostyn@theralase.com Download the brochure here

UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)

THERALASE WHITE PAPER NOW AVAILABLE! UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)

Low Level Laser Therapy (LLLT) is a rapidly growing modality used in rehabilitation and physical therapy. A number of safe and beneficial therapeutic effects of LLLT have been reported in numerous clinical conditions; however, despite many reports of positive findings from experiments conducted in-vitro, in animal models and in randomized controlled clinical trials worldwide, the use of this scientifically grounded, non-invasive, anti-inflammatory and regulatory modality has yet to find mainstream adoption by medical doctors. The aim of the White Paper is as follows: 1.    introduce the unfamiliar reader, with some medical background, to the contemporary concept of LLLT and its pathophysiological significance, 2.    review the role of the mitochondrial pathway in the mechanisms of LLLT, 3.    provide necessary practical guidance based on personal scientific and clinical experience, 4.    assist manufacturers in their research and development, 5.    help health care practitioners choose and use an adequate light therapy device 6.    outline the prospects of LLLT as an avenue to treat chronic inflammation and pain and to aid in an effective clinical practice. Go to www.theralase.com/www/whitepapers.php to download the white paper. Regards The Theralase Team

Current Research in Low Level Laser Therapy - Free Webinar Nov 16

CURRENT RESEARCH IN LOW LEVEL LASER THERAPY Register today for the webinar presentation  Date: Wednesday, November 16th, 2011 Time: 1:00 PM EST https://www2.gotomeeting.com/register/620293410 Below are a few items that will be covered in the Webinar: • 2011 Published Research • A Critical Review of Studies from Peer Reviewed Journals • Emerging Trends in Laser Research Regards, The Theralase Team www.theralase.com Theralase Laser Clinic Clinic Locator

Low Level Laser Therapy (LLLT): Why More is Less and What is Best

LLLT is a fast growing field of medicine recognized by every major industrialized nation in the world, offering painless, non-invasive and highly effective drug-free solutions. Able to treat a plethora of neural muscular skeletal conditions, LLLT is often the only solution that is available to the highly trained practitioner to control disease when conventional therapies have come up lacking.

Unfortunately, LLLT is yet to achieve universal recognition by the medical community due to the confusion in the marketplace caused by the many poorly designed clinical studies in the published literature promulgated by researchers who lack the formal training in the rigors of proper scientific and clinical study methodologies. These unscientific and poorly designed clinical studies do more harm than good for the LLLT field, as the large number of patients who could substantially benefit from this modern miracle called LLLT are denied the service because their attending practitioners remain unconvinced of the technology. I have used many different laser devices over the past 20 years in my career and I must say that no two lasers are created equal. The best therapeutic laser I have used is one from one of the oldest and most respected cold laser manufacturers in the world; namely, Theralase Inc., based out of Toronto, Canada. The Theralase TLC-1000 laser system is Health Canada, FDA and European Union approved as a class 3B superpulsed therapeutic medical laser device. The Theralase’s advanced LLLT proprietary technology encompasses potent and complementary bioregulatory mechanisms achieved using visible red 660 nm and near infrared superpulsed (NIR) 905 nm laser light.

The Theralase superpulsed laser has the distinction of being one of the fastest in the world - delivering pulses at 200 billionths of a second, producing average powers of 100 mW and peak powers up to 50,000 mW per diode. These unique parameters result in a higher concentration of light energy (I₀), or photon density at tissue depth versus any known competitive technology, without the risk of burning tissue.

While continuous wave (CW) and standard pulsed lasers (PW) are limited to less than 1 to 2 cm of therapeutically effective depth of penetration, the Theralase superpulsed (SP) NIR laser technology is able to demonstrate therapeutic effect at up to 10 cm below the tissue surface. This allows Theralase’s superpulsed technology to target deep tissue structures such as: bones, tendons, ligaments and cartilage. In the literature, Theralase’s 905 nm superpulsed technology has been proven to be more effective than a 905 nm CW laser treatment1, thus it is the superpulsing of the Theralase technology which creates this difference.

In conjunction with its 905 nm superpulsed technology, Theralase combines 660 nm continuous wave technology leading to a synergistic therapeutic effect operating via direct photochemical and photophysical cellular events. The therapeutic optical windows of 660 nm and 905 nm laser light utilised by Theralase’s LLLT technology correspond with the absorption and the action spectra optical windows of the key mitochondria chromophores, such as cytochrome c oxidase and the cellular membrane lipids. Moreover, it is apparent that 660 nm and 905 nm light have an impact on the mitochondrial chromophores via independent and nitric oxide mediated photochemical and photophysical mechanisms.1,2,3 Hence the combination of 660 nm and 905 nm light is  proven to have an additive biologic effect compared to any individual wavelengths. This biologic effect is further amplified by these two wavelengths activating and targeting the proximal and distal therapeutic mechanisms, in tissues, which induce bioregulatory responses that effectively modulate local and systemic pathologic manifestations in the Theralase LLLT treated patients.

According to Brown et al., mitochondria produce and consume nitric oxide (NO) and NO stimulates mitochondrial biogenesis, apparently via the upregulation of nucleotides like ATP and transcriptional factors like nuclear factor kappa B (Nf-kB).⁽⁴⁾

Therefore, it can be strongly suggested that the Theralase LLLT induced NO can reprogram cellular function, mainly via oxidative stress and changes of mitochondrial temperature gradient due to a process similar to selective photothermolysis, and thus initiate a cascade of local and systemic therapeutic signalling1. These signal transduction pathways may lead to increased cell activation and traffic, modulation of regulatory cytokines, growth factors and inflammatory mediators and expression of protective anti-apoptotic proteins.⁽⁵⁾⁽⁶⁾

The results of these molecular and cellular changes in animals and humans integrate such benefits as: increased healing in chronic wounds, improvements in sports injuries and carpal tunnel syndrome, pain reduction in arthritis and neuropathies, amelioration of damage after heart attacks, strokes or nerve injury and alleviation of chronic inflammation and toxicity.⁽⁷⁾⁽⁹⁾

There is certainly more than one reaction involved in the primary mechanisms of LLLT and there is reason to believe that all of these processes occur simultaneously when a tissue is irradiated. Experimental data clearly supports the use of 660 nm and 905 nm laser light as the best choices, based on their role in the modulation of redox mitochondrial function, changes in the properties of terminal enzymes and the cellular signalling that are critical steps in the bioregulatory mechanisms of LLLT.

In closing, I must report that there is a perplexity in the literature pertaining to the direct photoacceptor or the light absorbing chromophore for near infrared light (NIR). Manufacturer’s marketing materials are particularly rich with assumptions about the prime molecular photoacceptor and mechanisms of the light within the 800 to 880 nm range; however, the clinical literature shows no strong evidence that cytochrome c oxidase has strong absorption in the 800 to 880 nm range. Therefore, although photobiological effects in the 800 to 880 light range are ascribed to light absorption by mitochondrial cytochrome c oxidase, the low absorbance in this region makes scientists highly question it.⁽⁷⁾⁽⁹⁾

Class 3B versus Class 4 Lasers

There is a slew of false information in the public domain regarding the effectiveness and cellular mechanisms activated during class 4 laser light irradiation. Many class 4 laser manufacturers are intentionally or unintentionally misleading healthcare practitioners into believing that higher power and longer near infrared wavelengths equate to deeper tissue penetration and better clinical efficacy. Nothing could be further from the truth. Particularly disturbing are claims made by manufacturers of Class 4 laser technologies emitting in the 808, 880, 970 and 980 nm wavelengths.

Unfortunately, all of these claims turn out to be fancy sales gimmicks, as they have not the standing in the clinical or scientific journals to support their claims. The clinical and scientific facts are clear that because of the very high absorption of NIR laser light by water at wavelengths greater than 950 nm, 99% of the  energy produced at this wavelength or above is absorbed before penetrating the dermis of the skin, leading to a high risk of thermal damage and a low depth of penetration. Promoting that a laser is a class 4 laser states absolutely no information about the wavelength of the device, but simply informs the purchaser about the risk of thermal tissue damage. A CO2 laser (wavelength = 10,600 nm), for example, is a common class 4 laser that is absorbed in the first 10 microns (0.0004 inches) of tissue, thus primarily in the epidermis. The same holds for the excimer (XeCl, wavelength = 308 nm) laser which is also absorbed in the epidermis. At 970 and 980 nm, the depth of penetration is less than 300 microns (< 0.01 inches), thus total absorption is achieved within the dermis of the skin. For any given wavelength, the tissue properties are determined by the scattering and absorption coefficients of the specific tissue structures resident in the tissue. These scattering and absorption coefficients determine the penetration depths and ultimately govern the overall depth of penetration of a laser beam. Now a Class 4 laser typically has higher incident power and larger treatment area, but the depth of penetration is superficial and is restricted to a few hundred microns at best (i.e.: the top layer of the dermis). Even with higher incident powers and large treatment areas there is no biochemical effect due to lack of cellular mechanism activation; therefore, the thermal effects of a class 4 laser are the only mechanism of action remaining. Once the thermal effects of tissue have been exceeded, tissue damage is imminent.

Certain manufacturers use the limited knowledge of their customers to claim that a Class 4 laser has greater efficacy than a class 3B laser. This is unsubstantiated rubbish. Laser classification is only used according to IEC-825 guidelines to determine the possible risk for eye and skin damage and has nothing to do with the efficiency in treatment.  Laser classification is determined by not just a question of optical output power, but also wavelength, divergence of the beam, emission area, pulsing parameters, exposure rates, et cetera. Regarding Class 4 high power lasers, it has not been proven in the scientific and clinical literature that high power is better than low power, in fact the opposite has been proven to be true. As I have mentioned above, there is a therapeutic “optical” response window between 600 and 950 nm and a biphasic dose response curve governed by the Arndt-Schulz law, within which the positive bioregulatory effects occur.

The use of LLLT in animals and humans almost exclusively involves light in the range above 600 nm and below 950 nm with the maximum effective “optical window” ranging from 650 nm to 930 nm.⁽¹⁰⁾

As an example, a class 4 laser emitting 880 and 970 nm laser light at 10 W average power with a beam surface area of 10 cm² producing a radiant exposure of 1000 mW / cm², thus exceeding the safe exposure limits known as the Maximum Permissible Exposure limits (“MPE”), which range from 200 mW to 500 mW / cm² depending on wavelength. Therefore, these devices need to be treated as thermal invasive devices, period!

The use of class 4 lasers have a high potential of delivering non optimal treatment doses of energy due to their lack of penetration and excessive MPE; thus presenting a greater risk  of burning patients, particularly with dark hair follicles. Let’s say that you wish to deliver energy to a tissue surface of 1 cm² with a dose of 10 joules/cm² of energy. With a 10 Watt laser this takes one second of treatment time. If however you wished to deliver 2 to 4 joules of energy to the same surface area, which is a more common therapeutic dose, this would take 0.2 to 0.4 seconds. Most Class 4 manufacturers treat up to 5 minutes with their technology, thus they have exceeded the therapeutic dose of tissue not only in wavelength by being outside the optical window, but also in power by exceeding the MPE by 20 times and the therapeutic dose by 500 times. This logic suggests that too much power and the wrong wavelength simply equates to the expense of more money without the requisite return in better clinical effects. I therefore regard lasers with output powers exceeding 500 mW as unnecessarily strong and downright dangerous to conduct LLLT treatments.

Class 4 lasers for phototherapy is not new and not innovative, as such lasers have been on the market for years but have been approved strictly for surgical applications; such as: general surgery and tissue ablation for port wine stains, spider veins, et cetera. Just advertising the advantage that a laser is class 4 and hence, is a better instrument then a class 3B laser is akin to claiming that the Chrysler 600 is a better vehicle than the Mercedes Benz 500, just because the number is higher.

The above criticism is directed towards the gross generalizations and false claims of vendors of Class 4 lasers who purport their use for therapeutic purposes, not against the use of class 4 lasers for their eligible claims in laser surgery and tissue ablation. One thing remains certain, current scientific and clinical research proves that class 3B lasers are best suited for therapeutic applications and class 4 lasers are best suited for tissue destruction.

Bibliography:

1) In vivo effects of low level laser therapy on inducible nitric oxide synthase. Moriyama Y, Nguyen J, Akens M, Moriyama EH, Lilge L. 3, March 2009, Lasers Surg Med, Vol. 41, pp. 227 -231)

2) Primary and secondary mechanisms of action of visible to near-IR radiation on cells. T, Karu. 1, Mar 1999, Photochem Photobiol, Vol. 49, pp. 1-17

3) Mechanisms of Low Level Light Therapy, T.N, Hamblin M.R and Demidova. [ed.] SPIE. 2006. Vol. 614001

4) Nitric oxide and mitochondria. GC. Brown. 12, Jan 2007, Front Biosci, Vol. 1, pp. 1024-1033

5) Novel effects of nitric oxide. Davis KL, Martin E, Turko IV, Murad F. 2001, Annu Rev Pharmacol Toxicol, Vol. 41, pp. 203-236

6) Nitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin. Keswani SC, Bosch-Marcé M, Reed N, Fischer A, Semenza GL, Höke A. 12, Mar 2011, Proc Natl Acad Sci, Vol. 108, pp. 4986-4990

7) Cellular Cromophores and Signaling in Low Level Light Therapy. T, Hamblin M.R. and Demidova –Rice. [ed.] SPIE. 2011. Vol. 6428, pp. 642802-1

8) ((Powers L, Blumberg WE, Chance B, Barlow CH, Leigh JS Jr, Smith J, Yonetani T,Vik S, Peisach J. The nature of the copper atoms of cytochrome c oxidase as studied by optical and x-ray absorption edge spectroscopy. Biochim Biophys Acta. 1979 Jun 5; 546(3):520-38

9) Beinert H, Shaw RW, Hansen RE, Hartzell CR. Studies on the origin of the near-infrared (800-900 nm) absorption of cytochrome c oxidase. Biochim Biophys Acta. 1980 Jul 8; 591(2):458-70)

10) (Biostimulatory windows in low-intensity laser activation: lasers, scanners, and NASA's light-emitting diode array system. Sommer AP, Pinheiro AL, Mester AR, Franke RP, Whelan HT. 1, Feb 2001, Clin Laser Med Surg, Vol. 19, pp. 29-33)